- Home
- SCLXW vs NTRB Comparison
SCLXW vs NTRB Comparison
Compare SCLXW & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- NTRB
- Stock Information
- Founded
- SCLXW N/A
- NTRB 2016
- Country
- SCLXW United States
- NTRB United States
- Employees
- SCLXW 115
- NTRB N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- SCLXW Health Care
- NTRB Health Care
- Exchange
- SCLXW Nasdaq
- NTRB Nasdaq
- Market Cap
- SCLXW N/A
- NTRB 59.1M
- IPO Year
- SCLXW N/A
- NTRB N/A
- Fundamental
- Price
- SCLXW $0.07
- NTRB $5.68
- Analyst Decision
- SCLXW
- NTRB Buy
- Analyst Count
- SCLXW 0
- NTRB 1
- Target Price
- SCLXW N/A
- NTRB $13.00
- AVG Volume (30 Days)
- SCLXW 4.0K
- NTRB 55.1K
- Earning Date
- SCLXW 03-07-2025
- NTRB 05-30-2025
- Dividend Yield
- SCLXW N/A
- NTRB N/A
- EPS Growth
- SCLXW N/A
- NTRB N/A
- EPS
- SCLXW N/A
- NTRB N/A
- Revenue
- SCLXW $55,152,000.00
- NTRB $2,139,537.00
- Revenue This Year
- SCLXW N/A
- NTRB $571.50
- Revenue Next Year
- SCLXW N/A
- NTRB $577.37
- P/E Ratio
- SCLXW N/A
- NTRB N/A
- Revenue Growth
- SCLXW 22.02
- NTRB 2.60
- 52 Week Low
- SCLXW $0.18
- NTRB $3.35
- 52 Week High
- SCLXW $0.18
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- NTRB 48.01
- Support Level
- SCLXW N/A
- NTRB $5.00
- Resistance Level
- SCLXW N/A
- NTRB $8.11
- Average True Range (ATR)
- SCLXW 0.00
- NTRB 0.56
- MACD
- SCLXW 0.00
- NTRB 0.07
- Stochastic Oscillator
- SCLXW 0.00
- NTRB 21.86
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.